Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.

International journal of molecular sciences - 2 Oct 2023

Chen Wenjing, Park Jong-In

Abstract excerpt

BRAF is one of the most frequently mutated oncogenes, with an overall frequency of about 50%. Targeting BRAF and its effector mitogen-activated protein kinase kinase 1/2 (MEK1/2) is now a key therapeutic strategy for BRAF-mutant tumors, and therapies based on dual BRAF/MEK inhibition showed significant efficacy in a broad spectrum of BRAF tumors. Nonetheless, BRAF/MEK inhibition therapy is not always effective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm
Share to MAP Kinase Kinase 1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Melanoma and MAPK Pathways

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 37834284
DOI: 10.3390/ijms241914837
PMCID: PMC10573597

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.PMID 37834284Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read ↗

[Resistance to BRAF inhibitors: A lesson from clinical observations].Semantic proximity Read ↗

Defining and Targeting BRAF Mutations in Solid Tumors.Semantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated TumoursSemantic proximity Read ↗

BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical ApplicationsSemantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer.Semantic proximity Read ↗

Targeting the multifaceted BRAF in cancer: New directions.Semantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

[Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.